INH and Rifapentine Treatment for LTBI: Expert Opinions About 3HP Utilization

Webinar Materials: www.currytbcenter.ucsf.edu/trainings/3hp-webinar-materials/materials

90-Minute National Webinar
Originally aired March 17, 2016

This 90-minute training was created for physicians, nurses, and other health professionals who diagnose and treat patients with latent TB infection (LTBI).

The webinar will include a panel of experts discussing the questions healthcare providers have about using 3 months of isoniazid and rifapentine once weekly (3HP) to treat LTBI.

Please note:  This presentation contains information about the treatment of latent tuberculosis infection (LTBI). It was produced prior to the release of updated guidelines from the CDC in February 2020.  For the most current guidance available regarding LTBI treatment, please see: Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020

CME and CE units are not being offered for this recording and there is no participant evaluation

Faculty:

    Heidi Behm, RN, MPH
    TB Controller 
    Public Health Division
    Oregon Health Authority
    Portland, OR

    Marcos Burgos, MD
    Associate Professor/TB Medical Director
    TB Control Program
    New Mexico Department of Health
    Albuquerque, NM

    Neha Shah, MD, MPH
    Commander, US Public Health Service
    Centers for Disease Control and Prevention
    California Department of Public Health
    Richmond, CA

    Mai Vu, Pharm D
    Pharmacist
    Infectious Diseases Section
    San Francisco VA Medical Center
    San Francisco, CA